How specialist nurse-led care can help to lower the costs of prophylaxis

1 Richards M, Williams M, Chalmers E et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematology 2010; 149: 498;507.10.1111/j.1365-2141.2010.08139.x20230411Search in Google Scholar

2 Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003; 9 <Suppl 1=: 94;9..10.1046/j.1365-2516.9.s1.8.x12709044Search in Google Scholar

3 Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9 <Suppl. 1=: 101;8.10.1046/j.1365-2516.9.s1.4.x12709045Search in Google Scholar

4 Collins PW. Personalized prophylaxis. Haemophilia 2012; 18 <suppl. 4=: 131;5.10.1111/j.1365-2516.2012.02838.x22726096Open DOISearch in Google Scholar

5 Anwar M, Uprichard J, Austin SK. Discrepant one;stage clotting versus chromogenic FVIII assays in haemophilia patients on ReFacto AF. Oral presentation at British Society for Haematology, Annual Scientific Meeting, 2013.Search in Google Scholar